Cargando…

High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer

The present study aimed to investigate the association between excision repair cross-complementation group 1 (ERCC1) expression and clinical resistance to platinum-based chemotherapy or clinical characteristics, including survival time, in patients with epithelial ovarian cancer (EOC). ERCC1 express...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Pei, Wang, Yifeng, Chen, Liquan, Gan, Yaping, Wu, Qinian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950824/ https://www.ncbi.nlm.nih.gov/pubmed/27446360 http://dx.doi.org/10.3892/ol.2016.4732

Ejemplares similares

Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
por: Guffanti, Federica, et al.
Publicado: (2020)

ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy
por: Liblab, Salisa, et al.
Publicado: (2020)

Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
por: Tang, Ning, et al.
Publicado: (2017)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Platinum-Taxol non-cross resistance in epithelial ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1995)

COPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer
por: Zhang, Hongqin, et al.
Publicado: (2022)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy
por: Ryu, Hyewon, et al.
Publicado: (2017)

ERCC1 and ERCC2 Variants Predict Survival in Gastric Cancer Patients
por: Li, Yangkai, et al.
Publicado: (2013)

SERPINB3 in the Chicken Model of Ovarian Cancer: A Prognostic Factor for Platinum Resistance and Survival in Patients with Epithelial Ovarian Cancer
por: Lim, Whasun, et al.
Publicado: (2012)

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
por: Cui, Qingli, et al.
Publicado: (2021)

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer
por: Cantón-Romero, Juan Carlos, et al.
Publicado: (2017)

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy
por: Baiomy, Mohamed Ali EL, et al.
Publicado: (2017)

Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer
por: Li, Guoping, et al.
Publicado: (2020)

ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
por: Zhang, Yuqiang, et al.
Publicado: (2021)

Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma
por: Sung, Pi-Lin, et al.
Publicado: (2015)

Correction: SERPINB3 in the Chicken Model of Ovarian Cancer: A Prognostic Factor for Platinum Resistance and Survival in Patients with Epithelial Ovarian Cancer
por: Lim, Whasun, et al.
Publicado: (2013)

Evaluation of nuclear NF-κB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors
por: Azambuja, Alan A., et al.
Publicado: (2020)

Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism
por: Leung, Dilys, et al.
Publicado: (2022)

The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
por: Rulli, Eliana, et al.
Publicado: (2016)

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
por: Pchejetski, Dmitri, et al.
Publicado: (2015)

Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer
por: Gulia, Seema, et al.
Publicado: (2020)

TIMP-1 Is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells
por: Sonego, Maura, et al.
Publicado: (2019)

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022)

Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy
por: Hlaváč, Viktor, et al.
Publicado: (2022)

A common polymorphism in the 5′ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy
por: Somers, Joanna, et al.
Publicado: (2015)

Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer
por: Sheng, W.J., et al.
Publicado: (2013)

Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells
por: Pastò, Anna, et al.
Publicado: (2016)

ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer
por: Chebouti, Issam, et al.
Publicado: (2016)

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer
por: Han, Gwan Hee, et al.
Publicado: (2023)

The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy
por: LIU, YONG-PING, et al.
Publicado: (2013)

Functional characterization of a novel transcript of ERCC1 in chemotherapy resistance of ovarian cancer
por: Liu, Jia, et al.
Publicado: (2017)

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer
por: Smith, G, et al.
Publicado: (2012)

High Expression of PARP1 in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2022)

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2023)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells
por: Sonego, Maura, et al.
Publicado: (2017)

Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer
por: Normann, Marius C., et al.
Publicado: (2019)

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Sun, Li, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t60p2sgsq7qpvt36jbdvhs8l75